VICTORY is an international multicentre pilot study to investigate the safety and efficacy of Vinblastine with Tovorafenib in paediatric and young adult patients with recurrent or progressive RAF altered (non-NF1) LGG. The study will occur in two phases; Phase A focuses on dose finding and feasibility, while Phase B assesses overall efficacy. The primary objective is to determine the maximum tolerated dose (MTD/RP2D) of combination of vinblastine + tovorafenib, and to determine overall response rate of CR, PR and MR in patients with LGG treated with combination of vinblastine + tovorafenib by RANO-LGG criteria.